From theheart.org on Medscape

Coverage from the

American Heart Association (AHA) 2016 Scientific Sessions

November 12 - 16, 2016; New Orleans, Louisiana

November 12 - 16, 2016 New Orleans, Louisiana

Booth 3127

The Cardiology Show

The Cardiology Show From AHA 2016 With Dr Valentin Fuster UPDATED with Transcript // PRECISION, PIONEER-AF-PCI, ART, EUCLID, and the cognition substudy of HOPE-3 are the five stars, but the panel also reviews additional trials on novel approaches to lipids management and heart failure.

Meeting Highlights at a Glance

Top News From AHA 2016: Slideshow Highlights include long-awaited results from the PRECISION trial, plus iron-repletion therapy for heart failure and coronary disease progression on PCSK9 inhibitors.

Conference News

AHA No Added Value to Spironolactone in Acute HF: ATHENA-HF
Heartwire from Medscape, November 30, 2016
AHA Early-Pregnancy Glucose May Best OGTT as Congenital HD Predictor
November 29, 2016
AHA Betrixaban in Acutely Ill Bests Enoxaparin Against Strokes: APEX
Heartwire from Medscape, November 29, 2016
AHA Popular Heartburn Medication Linked to Increased Stroke
Medscape Medical News, November 29, 2016
AHA Subclinical AF Common in ASSERT 2, Stroke Implications Unclear
Heartwire from Medscape, November 28, 2016
AHA FFR-Guided PCI: FUTURE Still Seen As Bright After Halted Trial
Heartwire from Medscape, November 28, 2016
AHA Gene for Strong Bitter Taste Tied to Higher Sodium Intake
Heartwire from Medscape, November 25, 2016
AHA ORION-1: Novel PCSK9 Inhibitor Provides Durable LDL-C Reduction
Heartwire from Medscape, November 23, 2016
AHA Marijuana Use Can Double Risk of Takotsubo Cardiomyopathy
Heartwire from Medscape, November 22, 2016
AHA Two-Fifths of 'SCD' Not Even Cardiac in Postmortem Study
Heartwire from Medscape, November 22, 2016
AHA PARADIGM-HF: MRA and Sacubitril/Valsartan Cut Hyperkalemia Risk
Heartwire from Medscape, November 22, 2016
AHA 'Disturbingly' High, Variable Costs Seen for Generic HF Meds
Heartwire from Medscape, November 21, 2016
AHA Iron Supplementation in HF: Trials Support IV but Not Oral
Heartwire from Medscape, November 18, 2016
AHA Interatrial Shunt Promising for Heart Failure With Preserved Ejection Fraction
Heartwire from Medscape, November 17, 2016
AHA Dabigatran Antidote Fast, Effective in RE-VERSE AD: Now What?
Heartwire from Medscape, November 17, 2016
AHA MOMENTUM 3: Fewer Reoperations With HeartMate 3 at 6 Months
Heartwire from Medscape, November 17, 2016

AHA MILANO PILOT Clouds Promise of Infusible ApoA-1 for CAD
Heartwire from Medscape, November 16, 2016
AHA Aggressive BP Therapy Won't Stop AF Recurrences After Ablation
Heartwire from Medscape, November 15, 2016
AHA GLAGOV: Evolocumab Shows Atheroma Reduction on Top of Statins
Heartwire from Medscape, November 15, 2016
AHA Prior Incomplete Revascularization Ups Noncardiac-Surgery MI Risk
Heartwire from Medscape, November 15, 2016
AHA TRUE-AHF Shakes Up Beliefs About Acute Heart-Failure Therapy
Heartwire from Medscape, November 15, 2016
AHA ART: No Gain From Bilateral vs Single IMA Bypass Graft
Heartwire from Medscape, November 14, 2016
AHA TAVI Mortality Higher vs SAVR in Intermediate-Risk Patients
Heartwire from Medscape, November 14, 2016
AHA New Strategies for AF Patients Undergoing PCI Cut Bleeding
Heartwire from Medscape, November 14, 2016
AHA USPSTF Finalizes Statin Recommendations for CVD Prevention
Medscape Medical News, November 14, 2016
AHA PRECISION: Celecoxib Similar to Ibuprofen, Naproxen for CV Risk
Heartwire from Medscape, November 13, 2016
AHA Statin Did Not Harm, BP Therapy Did Not Help Cognition: HOPE-3
Heartwire from Medscape, November 13, 2016
AHA EUCLID: Ticagrelor, Clopidogrel in PAD Similar for CV Events
Heartwire from Medscape, November 13, 2016
AHA Exenatide Disappoints in Cardiac Arrest
Medscape Medical News, November 12, 2016
AHA Bystander CPR in Kids: Add Breaths to Compressions for Best Results
Heartwire from Medscape, November 12, 2016
AHA New Orleans on the Map With Mardi Gras, the Saints, and AHA 2016
Heartwire from Medscape, November 8, 2016

Popular AHA 2015 News

SPRINT Would Cut BP Target to Less Than 120 mm Hg in High-CV-Risk Patients with HTN, No Diabetes UPDATED // Full results of the much-anticipated trial have been released to a variety of expert opinions. Some are calling for updated hypertension guidelines, but exclusions and high adverse-event rates raise concern.
Medscape Medical News, Nov 9, 2015
Rethink Continuous-Compression CPR by EMS: Randomized Trial In the largest trial of its kind, interruptions for rescue breaths led to better outcomes than continuous compressions; the new AHA guidelines on CPR by EMS may need revision sooner than expected.
Medscape Medical News, Nov 10, 2015
Focus More on % LDL Reductions: New JUPITER Data Clinicians need to pay more attention to percent reduction in LDL cholesterol, rather than just focusing of actual LDL levels, Dr Paul Ridker says.
Medscape Medical News, Nov 13, 2015

© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives from AHA

STICH Women: Don't Shy Away From Surgery in HFrEF
Ileana L. Piña, MD, MPH
'One Brave Idea' Recipient on Predicting Who Will Develop CAD
Michelle L. O'Donoghue, MD, MPH;
Calum A. MacRae, MD, PhD
Is CT Angiography Overkill for Low-Risk Chest Pain?
John M. Mandrola, MD;
Andrew J. Foy, MD
SMAC AF: BP-Lowering Alone Won't Improve Ablation Success
John M. Mandrola, MD;
Jonathan P. Piccini, MD, MHS
TRUE-AHF: Better to Prevent vs Treat Acute Decompensation
Ileana L. Piña, MD, MPH; Milton Packer, MD
Any HOPE(-3) for Staving off Age-Related Cognitive Decline?
John M. Mandrola, MD; Jackie Bosch, PhD

Bloggers from the Floor

Mr Trump: Please Repeal HRRP ASAP Dr Melissa Walton-Shirley attended a session HF readmissions and has a suggestion for the president-elect.
Hypercoagulable States: On Clots and Other Things Dr Melissa Walton-Shirley finds what she's looking for on day 2 of the AHA meeting in a session on hypercoagulable states.
America: Dumb to Tempt More Pot-Related CV Complications Dr Melissa Walton-Shirley recounts a presentation on the association of cannabis with takotsubo cardiomyopathy and discusses recent legalization efforts in several states and what it might mean.
AHA: Technology Delivers Little Improvement in AF Ablation Success Despite thrilling advances in technology, a study presented at the AHA meeting reveals little progress in AF ablation success. Dr John Mandrola explores reasons for this plateau.
Bad Policy Is as Harmful as Bad Medicine Dr John Mandrola's take on a presentation of outcomes vs adherence to performance measures in managing patients with heart failure.
AHA 2016: How Do NOAC Drugs Fare Against Well-Managed Warfarin? Although NOAC drugs compare favorably with warfarin in patients with AF, questions remain about the differences when warfarin is well managed. Dr Mandrola reports on a provocative observational study from Sweden, where warfarin management is superior.
Mandrola Previews AHA 2016 Dr John Mandrola takes a look at the late-breaking clinical trials and other presentations coming up at the American Heart Association Scientific Sessions this weekend in New Orleans.

Previous Coverage